To view the fulltext, please log in
To view the pdf, please log in
- FullText & PDF
- Unlimited re-access via MyKarger (new!)
- Unrestricted printing, no saving restrictions for personal use
- Reduced rates with a PPV account
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restriction apply
Rental: USD 8.50
Cloud: USD 20.00
- Automatic perpetual access to all articles of the subscribed year(s)
- Unlimited re-access via Subscriber Login or MyKarger
- Unrestricted printing, no saving restrictions for personal use
Article / Publication Details
Identification of a small animal model that undergoes pathological temporomandibular joint (TMJ) degeneration would represent a significant research tool. To date however, no such model has been described. We therefore have investigated the pathological and immunohistochemical features of the TMJ of a transgenic mouse that over expresses the human form of TNFα. The TMJ of this animal appears to undergo changes that resemble arthriditics of temporomandibular dysfunction. Furthermore, the disc and articular cells express MMP9 and IL-1. Future work should validate this animal model as one that would have utility for the study of TMJ disorders. Maintenance of connective tissues in joints such as the TMJ is a normal process that allows for the reconstitution of important anatomic features. This maintenance involves both the removal and re-synthesis of structural proteins such as collagens, elastins and proteoglycans. An imbalance in the pathways for degradation and synthesis can lead to the degeneration of joint tissues. We describe the presence of a matrix metalloproteinase, MMP9 (92-kD gelatinase), in TMJ disc and articular cells that likely function in the degradative process. Additionally, we show that this enzyme is under the control of pro-inflammatory cytokines whereby TGFβ and IL-1 stimulate and PGE2 inhibits its activity.
Article / Publication Details
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Clark, G.T. (1987) Diagnosis and treatment of painful temporomandibular disorders. Dent Clin N Am 31: 645–674.
- Clark, G.T., R. Mulligan (1984) A review of the prevalence of temporomandibular joint dysfunction. Gerodontology 3: 232–236.
- Bonacci, C.E., S.B. Syrop, N. Gold, H. Israel (1992) Temporomandibular/facial pain. NYS Dent J 58: 30–33.
- De Bont, L.G.M., G. Boering, R.S.B. Liem, F. Eulderink, P.L. Westesson (1986) Osteoarthritis and internal derangement of the temporomandibular joint: A light microscope and scanning electron microscope study. J Oral Maxillofac Surg 44: 634–643.
- Keffer, J., L. Prokert, H. Cazlaris, S. Georgopoulos, E. Karlaris, D. Kioussis, G. Kollias (1991) Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 10: 4025–4031.
- Angel, P., M. Karin (1992) Specific members of the Jun protein family regulate collagenase expression in response to various extracellular stimuli; in Birkedal-Hansen, H., Z. Werb, H.G. Welgus, H.E. Van Wart (eds): Matrix Metallo-Proteinases and Inhibitors. Matrix. Special Suppl No 1. Stuttgart, Gustav Fischer, pp 156–164.
- Salo, T., F. Lyons, H. Rahemtulla, H. Birkedal-Hansen, H. Larjava (1991) Transforming growth factor beta 1 up regulates type IV collagenase expression in cultured human keratinocytes. J Biol Chem 266: 11436–11441.
- Giraudon, P., N. Thomasset, A. Bernard, B. Verrier, MF. Belin (1995) Induction of MMP9 (92 kDa gelatinase) activity and expression of tissue inhibitor of metalloproteinase-2 mRNA (TIMP-2) in primitive neuroectodermal cells infected with retrovirus HTLV-I. Eur J Neurosci 7: 841–848.
- Tanaka, K., Y. Iwamoto, Y. Ito, T. Ishibashi, Y. Nakabeppu, M. Sekiguchi, Y. Sugioka (1995) Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res 55: 2927–2935.
- Twining, S.S., S.E. Kirschner, L.A. Mahnke, D.W. Frank (1993) Effect of Pseudomonas aeruginosa elastase, alkaline protease, and exotoxin A on corneal proteinases and proteins. Invest Ophthalmol Vis Sci 34: 2699–2712.
- Baylis, H.A., A. Megson, R. Hall (1995) Infection with Theileria annulata induces expression of matrix metalloproteinase 9 and transcription factor AP-1 in bovine leucocytes. Mole Biochem Parasitol 69: 211–222.
- Martin, J., J. Knowlden, M. Davies, JD. Williams (1994) Identification and independent regulation of human mesangial cell metalloproteinases. Kidney Int 46: 877–885.
- Hyuga, S., Y. Nishikawa, K. Sakata, H. Tanaka, S. Yamagata, K. Sugita, S. Saga, M. Matsuyama, S. Shimizu (1994) Autocrine factor enhancing the secretion of M(r) 95,000 gelatinase (matrix metalloproteinase 9) in serum-free medium conditioned with murine metastatic colon carcinoma cells. Cancer Res 54: 3611–3616.
- Sato, H., M. Seike (1993) Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395–405.
- Sato, H., M., Kita, M. Seiki (1993) v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to the retinoblastoma control elements. J Biol Chem 268: 23460–23468.
- Lengyel, E., R. Gum, J. Juarez, G. Clayman, M. Seiki, H. Sato, D. Boyd (1995) Induction of 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res 55: 963–967.
- Redini, F., J.-P. Pujol, L. Robert, W. Hornebeck (1998) Effect of cytokines and growth factors on the expression of elastase activity by human synoviocytes, dermal fibroblasts and rabbit articular chondrocytes. Biochem Biophys Res Commun 155: 786–793.
- Mothai, M., R.L. Smith, D.J. Schurman, Y. Tsuji, F. Torti, N.I. Hutchinson, W.G. Stetler-Stevenson, G.I. Goldberg (1993) Expression of the 92-kD type IV collagenase and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 92: 179–185.
- Mainardi, C.L., K.A. Hasty, M.S. Hibbs (1987) Collagen degradation by inflammatory phagocytes. J Rheumatol 14(suppl 14): 59–63.
- Murphy, G., J.J. Reynolds, U. Bretz, M. Baggiolini (1982) Partial purification of collagenase and gelatinase from human polymorphonuclear leukocytes: Analysis of their actions on soluble and insoluble collagens. Biochem J 203: 209–221.
- Lyons, J.G., B. Birkedal-Hansen, W.G.I. Moore, R.L. O’Grady, H. Birkedal-Hansen (1991) Characteristics of a 95-kDa matrix metalloproteinase produced by mammary carcinoma cells. Biochemistry 30: 1449–1456.
- Wilhelm, S.M., I.E. Collier, B.L. Marmer, A.Z. Eisen, G.A. Grant, G.I. Goldberg (1989) SV40-transformed human lung fibroblasts secrete a 92 kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 264: 17213–17221.
- Irby, W.B., M.R. Zetz (1983) Osteoarthritis and rheumatoid arthritis affecting the temporomandibular joint; in Laskin, D., W. Greenfield, E. Gale, J. Rugh, P. Neff, C. Alling, W. Ayer (eds): The President’s Conference on the Examination, Diagnosis, and Management of Temporomandibular Joint Disorders. Chicago, American Dental Association, pp 106–111.
- Scapino, R.P. (1983) Histopathology associated with malposition of the human temporomandibular joint disc. J Oral Surg 55: 382–397.
- Malemud, C.J., J. Martel-Pelletier, J.P. Pelletier (1987) Degradation of extracellular matrix in osteoarthritis: Four fundamental questions. J Rheumatol 14(suppl 14): 20–22.
- Woessner, J.F., Jr. (1992) Literature on vertebrate matrix metalloproteinases and their tissue inhibitors; in Birkedal-Hansen, H., Z. Werb, H.G. Welgus, H.E. Van Wart (eds): Matrix Metallo-Proteinases and Inhibitors. Matrix, Special Suppl No 1. Stuttgart, Gustav Fischer, pp 425–501.
- Senior, R.M., G.L. Griffin, C.J. Fliszar, S.D. Shapiro, G.I. Goldberg, H.G. Welgus (1991) Human 92- and 72 kilodalton type IV collagenases are elastases. J Biol Chem 266: 7870–7875.
- Helmy, E., R. Bays, S. Offenbacher (1990) Internal derangement: Is it a primary inflammatory disorder? J Dent Res 69: 866.
- Kopp, S., B. Wenneberg, E. Clemensson (1983) Clinical, microscopical and biochemical investigation of synovial fluid from temporomandibular joints. Scand J Dent Res 91: 33–41.
- Kerr, L.D., J.T. Holt, L.M. Matrisian (1998) Growth factors regulate transient gene expression by c-fos-dependent and c-fos-independent pathways. Science 242: 1424–1427.
- Kerr, L.D., N.E. Olashaw, L.M. Matrisian (1988) Transforming growth factor β1 and cAMP inhibit transcription of epidermal growth factor and oncogene-induced transient RNA. J Biol Chem 263: 16999–17005.
- Dayer, J.M., B. Beutler, A. Cerami (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163–2168.
- Blaine, T.A., P.F. Pollice, R.N. Rosier, P.R. Reynolds, J.E. Puzas, R.J. O’Keefe (1997) Modulation of the production of cytokines in titanium stimulated human peripheral blood monocytes by pharmacological agents: The role of cAMP mediated signaling mechanisms. J Bone Joint Surg 79A: 1519–1528.
- Neuner, P., G. Klosner, E. Schauer, M. Pournojib, W. Macheiner, C. Grunwald, R. Knobler, A. Schwarz, T.A. Luger, T. Schwarz (1994) Pentoxifylline in vivo down-regulates the release of IL-1B, IL-6, IL-8, and tumor necrosis factor-a by human peripheral blood mononuclear cells. Immunology 83: 262–267.